Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase NA 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Leukemia, Myeloid, Acute 99Myelodysplastic Syndromes 56Leukemia, Myelomonocytic, Chronic 23Leukemia 17Recurrence 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Non-Hodgkin 10Hematologic Neoplasms 9Multiple Myeloma 8Hodgkin Disease 8Neoplasms 6Myeloproliferative Disorders 6Leukemia, Myeloid 6Leukemia, Lymphocytic, Chronic, B-Cell 6Carcinoma, Non-Small-Cell Lung 6Myelodysplastic-Myeloproliferative Diseases 5Lymphoma 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Sarcoma 4Primary Myelofibrosis 4Ovarian Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Leukemia, Biphenotypic, Acute 4Head and Neck Neoplasms 4Anemia, Refractory, with Excess of Blasts 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Melanoma 3Lymphoma, T-Cell, Peripheral 3

Interventions

Radiotherapy 39pembrolizumab 37Carboplatin 37Cisplatin 34Paclitaxel 26Pemetrexed 24Docetaxel 18Nivolumab 17Magnetic Resonance Spectroscopy 17Gemcitabine 17Bevacizumab 17Specimen Handling 16Cyclophosphamide 15osimertinib 14Radiation 13Irinotecan 13Etoposide 13Erlotinib Hydrochloride 12durvalumab 11Topotecan 10Cetuximab 10Radiosurgery 9Immunoglobulin G 8Fluorouracil 8Everolimus 8Disulfides 8Celecoxib 8fludarabine 7Taxes 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Lung Neoplasms × Azacitidine × Clear all
NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Celgene

Phase 1 Completed
89 enrolled
BreastCNSDermatologicGenitourinaryGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioblastoma, Hodgkin Disease, Kidney Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Skin Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Small Cell Lung Carcinoma

NCT01545947 2019-11-12

Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

Celgene

Phase 1 Completed
76 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡